Cited by 430Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Clarke, Noel W., Armstrong, Andrew J., Thiery-Vuillemin, Antoine, Oya, Mototsugu, Shore, Neal, Loredo, Eugenia, Procopio, Giuseppe, de Menezes, Juliana, Girotto, Gustavo, Arslan, Cagatay, Mehra, Niven, Parnis, Francis, Brown, Emma, Schlürmann, Friederike, Joung, Jae Y., Sugimoto, Mikio, Virizuela, Juan A., Emmenegger, Urban, Navratil, Jiri, Buchschacher, Gary L., Poehlein, Christian, Harrington, Elizabeth A., Desai, Chintu, Kang, Jinyu, Saad, Fred·2022·NEJM Evidence

DOI 10.1056/evidoa2200043

Open this paper in CoChat — free account

Abstract

BACKGROUND: Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined antitumor effect when the poly(adenosine diphosphate[ADP]-ribose) polymerase inhibitor olaparib is combined with next-generation hormonal agent abiraterone to treat metastatic castration-resistant prostate cancer (mCRPC). METHODS: We conducted a double-blind, phase 3 trial of abiraterone and olaparib versus abiraterone and placebo in patients with mCRPC in the first-line setting. Patients were enrolled regardless of homologous recombination repair gene mutation (HRRm) status. HRRm status was determined following enrollment by tumor tissue and circulating tumor DNA tests. Patients were randomly assigned (1:1) to receive abiraterone (1000 mg once daily) plus prednisone or prednisolone with either olaparib (300 mg twice daily) or placebo. The primary end point was imaging-based progression-free survival (ibPFS) by investigator assessment. Overall survival was among the secondary end points. RESULTS: At this planned primary analysis at the first data cutoff, median ibPFS was significantly longer in the abiraterone and olaparib arm than in the abiraterone and placebo arm (24.8 vs. 16.6 months; hazard ratio, 0.66; 95% confidence interval [CI], 0.54 to 0.81; P<0.001) and was consistent with blinded independent central review (hazard ratio, 0.61; 95% CI, 0.49 to 0.74). At this data cutoff, overall survival data were immature (28.6% maturity; hazard ratio, 0.86; 95% CI, 0.66 to 1.12; P=0.29). The safety profile of olaparib and abiraterone was consistent with the known safety profiles of the individual drugs. The most common adverse events in the abiraterone and olaparib arm were anemia, fatigue/asthenia, and nausea. CONCLUSIONS: At primary analysis at this first data cutoff, abiraterone combined with olaparib significantly prolonged ibPFS compared with abiraterone and placebo as first-line treatment for patients with mCRPC enrolled irrespective of HRRm status. (Funded by AstraZeneca and Merck Sharp & Dohme, LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA; ClinicalTrials.gov number, NCT03732820.)

Integrity signals

Registry

Crossref · 10.1056/evidoa2200043

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
A Multiple Testing Procedure for Clinical Trials
O'Brien, P. C., & Fleming, T. R. (1979) · Biometrics · doi:10.2307/2530245 · Cited by 3,311
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
Sweeney, C. J., Chen, Y., Carducci, M. A., Liu, G., Jarrard, D. F., Eisenberger, M. A., Wong, Y., Hahn, N. M., Kohli, M., Cooney, M. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503747 · Cited by 2,958
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Olaparib for Metastatic Castration-Resistant Prostate Cancer
de Bono, J., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911440 · Cited by 2,323
Self-citation
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
James, N. D., Sydes, M. R., Clarke, N. W., Mason, M. D., Dearnaley, D. P., Spears, M. R., Ritchie, A. W. S., Parker, C. C., Russell, J. M., Attard, G., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)01037-5 · Cited by 2,007
Self-citation
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C. S., Basch, E., Fizazi, K. S., Antonarakis, E. S., Beer, T. M., Carducci, M. A., Chi, K. N., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.2702 · Cited by 1,707
Self-citation
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
Ryan, C. J., Smith, M. R., Fizazi, K., Saad, F., Mulders, P. F. A., Sternberg, C. N., Miller, K., Logothetis, C. J., Shore, N. D., Small, E. J., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71205-7 · Cited by 1,369
Self-citation
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022485 · Cited by 792
Self-citation

Show all 27 references

Sorted by citations

Items 201–300 of 430

Real-world experience in treatment outcome and genomic insights for metastatic prostate neuroendocrine carcinoma
Lai, J., Peng, Y., Chang, P. M., Chang, Y., Chung, H., Huang, Y.-H., Lin, T., Huang, W. J., Wei, T.-C., Huang, T.-H., et al. (2025) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000001209 · Cited by 5
Targeted Therapies in the Most Common Advanced Solid Tumors, Drug Resistance, and Counteracting Progressive Micrometastatic Disease: The Next Frontier of Research
Nicolini, A., Ferrari, P., Silvestri, R., & Bini, D. A. (2025) · MedComm · doi:10.1002/mco2.70373 · Cited by 5
Abigene, a Prospective, Multicentric Study of Abiraterone Acetate Pharmacogenetics in Metastatic Castration-Resistant Prostate Cancer
Ferrero, J.-., Mahammedi, H., Gravis, G., Roubaud, G., Beuzeboc, P., Largillier, R., Borchiellini, D., Linassier, C., Ebran, N., Pacé-Loscos, T., et al. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15020651 · Cited by 5
Utility and Clinical Application of Circulating Tumor DNA (ctDNA) in Advanced Prostate Cancer
Kostos, L. K., Fettke, H., Kwan, E. M., & Azad, A. (2023) · Société Internationale d’Urologie Journal · doi:10.48083/rfsh8912 · Cited by 5
Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits
Madan, R. A., Karzai, F. H., VanderWeele, D. J., Cheng, H. H., & Bono, J. S. D. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.01502 · Cited by 5
Poly (ADP-ribose) Polymerase Inhibitors in Patients with Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Zheng, C., Wang, Z., Li, L., Jiang, Y., Tang, Y., Wang, Y., Hao, X., Zhang, C., Guo, X., Yu, W., et al. (2023) · Medicina · doi:10.3390/medicina59122198 · Cited by 4
The 5-WS of targeting DNA-damage repair (DDR) pathways in prostate cancer
Guida, A., Mosillo, C., Mammone, G., Caserta, C., Sirgiovanni, G., Conteduca, V., & Sergio Bracarda, A. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102766 · Cited by 4
Expanding PARP Inhibitor Use in Prostate Cancer Beyond DNA Repair Defects
dos Reis, A. F. P., Faulkner, L. G., Lai, I. W., Dev, H., & Pacey, S. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103804 · Cited by 4
Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance
Gao, S., Patten, N. D., & Cai, C. (2025) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2025.05.003 · Cited by 4
Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer
Yusoh, N. A., Su, L., Chia, S. L., Tian, X., Ahmad, H., & Gill, M. R. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70093 · Cited by 4
Clinical Impact of Next-Generation Sequencing–Guided Targeted Therapies in Advanced Cancer: A Systematic Review and Meta-Analysis
Kazmi, F., Katyal, R., Liu, T. F. D., Gkogkou, P., Blagden, S. P., Lord, S., Dodwell, D. J., & Shrestha, N. (2025) · Clinical Oncology · doi:10.1016/j.clon.2025.103943 · Cited by 5
Can PARP Inhibitors Benefit Patients with Homologous Recombination Repair-Proficient Castration-Resistant Prostate Cancer? A Meta-analysis
Zhou, S., Desai, D., Kishi, N., Benjamin, S., & Tsao, C. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01188-8 · Cited by 4
Exploring DNA Damage Repair Therapeutics in Prostate Cancer beyond BRCAness
Costanzo, F. D., Williamson, J., Robson, C. N., Gaughan, L., Conteduca, V., Mansour, W. Y., Formisano, L., Demichelis, F., Oing, C., & Rescigno, P. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-23-0724 · Cited by 4
Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer
Thapa, B., Venturini, J., Choudhury, A. D., & Francini, E. (2026) · Cancers · doi:10.3390/cancers18111702 · Cited by 4
Enhanced Telehealth in Prostate Cancer
Bange, E. M., Reiner, A. S., Liebertz, C., Malling, C. D., Kuperman, G. J., Daly, B., Chimonas, S. C., Marcinkowski, K., Doshi, S. D., Polubriaginof, F. C. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.17466 · Cited by 4
Matching BRCA and prostate cancer in a public health system: Report of the Italian Society for Uro-Oncology (SIUrO) consensus project
Lapini, A., Caffo, O., Conti, G. N., Pappagallo, G. L., Re, M. D., D’Angelillo, R. M., Capoluongo, E., Castiglione, F., Brunelli, M., Iacovelli, R., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.103959 · Cited by 4
Mainstream Model of Genetic Testing for Prostate Cancer at a Large Tertiary Cancer Centre
Wang, X., Waldman, L., Silberman, Y., Wang, M. L., Tackey, C., Hanna, L., Vesprini, D., Emmenegger, U., Eisen, A. F., & Smoragiewicz, M. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.02.003 · Cited by 4
Self-citation
Olaparib monotherapy or in combination with abiraterone for treating mutated metastatic castration-resistant prostate cancer: alone or stronger together?
Fenton, S. E., & Hussain, M. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2391828 · Cited by 5
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Mehra, N., Antonarakis, E. S., Park, S. H., Goh, J. C. H., McDermott, R., González, N. S., Fong, P. C. C., Greil, R., Santis, M. D., Yanez, P. E., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.04.018 · Cited by 4
Self-citation
Metastatic castrate-resistant prostate cancer: a new horizon beyond the androgen receptors
Roy, S., & Fred Saad, C. (2022) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000620 · Cited by 4
Is It Time to Anticipate the Use of PARP Inhibition in Prostate Cancer Patients?
Sciarra, A., Santarelli, V., Santodirocco, L., Frisenda, M., Salciccia, S., Casale, P., Forte, F., Mariotti, G., Moriconi, M., Cattarino, S., et al. (2023) · Current Oncology · doi:10.3390/curroncol30090584 · Cited by 4
Combining Novel Hormonal Therapies with a Poly (ADP-Ribose) Polymerase Inhibitor for Metastatic Castration-Resistant Prostate Cancer: Emerging Evidence
Yang, J., Xiong, X., Zheng, W., Liao, X., Xu, H., Yang, L., & Wei, Q. (2023) · Current Oncology · doi:10.3390/curroncol30120751 · Cited by 4
Tale of two zones: investigating the clinical outcomes and research gaps in peripheral and transition zone prostate cancer through a systematic review and meta-analysis
Ali, A., Elumalai, T., Venkatesulu, B., Hekman, L., Mistry, H. B., Sachdeva, A., Oliveira, P., Clarke, N. W., Baena, E., Choudhury, A., et al. (2024) · BMJ Oncology · doi:10.1136/bmjonc-2023-000193 · Cited by 4
Self-citation
Expert Consensus Recommendations on the Management of Treatment-emergent Adverse Events Among Men with Prostate Cancer Taking Poly-ADP Ribose Polymerase Inhibitor + Novel Hormonal Therapy Combination Therapy
Shore, N. D., Broder, M. S., Barata, P. C., Crispino, T., Fay, A. P., Lloyd, J. L. E., Mellado, B., Matsubara, N., Pfanzelter, N., Schlack, K., et al. (2024) · European Urology Oncology · doi:10.1016/j.euo.2024.05.009 · Cited by 4
Self-citation
Talazoparib for the treatment of prostate cancer
Narang, A., Chehade, C. H., Özay, Z. İ., Nordblad, B., Swami, U., & Agarwal, N. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2397002 · Cited by 4
Diagnosis and Management of Skin Toxicities in Systemic Treatment of Genitourinary Cancers
Chowdhury, D., Chin, L. D., Odabashian, R., Fawaz, A., Canil, C., Ong, M., Kirchhof, M. G., Reaume, M. N., Beltran-Bless, A.-A., Savard, M.-F., et al. (2025) · Cancers · doi:10.3390/cancers17020251 · Cited by 4
Adding PARP inhibitor to an androgen-receptor signaling inhibitor in metastatic prostate cancer: what are we missing?
Giorgi, U. D., Giunta, E. F., Verzoni, E., & Procopio, G. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.06.008 · Cited by 4
Self-citation
False-Positive Circulating Tumor DNA Results Do Not Explain Lack of Efficacy for PARP Inhibitors in Patients With Castration-Resistant Prostate Cancer Harboring ATM and CHEK2 Mutations
Fallah, J., Xu, J., Joeng, H., Weinstock, C., Heiss, B. L., Maguire, W. F., Gao, X., Cheng, J., Chang, E., Agrawal, S., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00354 · Cited by 4
Comparative therapeutic efficacy and safety of first-line and second-line therapies for metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
Jiang, B., Wang, B., Chen, Y., Chen, Y., Li, B., & Bi, J. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103129 · Cited by 3
Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration‐Resistant Prostate Cancer: PROpel Subset Analysis
Oya, M., Joung, J. Y., Lee, J. Y., Sugimoto, M., Choi, Y. D., Hong, J. H., Uemura, H., Nishimura, K., Tsumura, H., Kawakami, S., et al. (2025) · Cancer Science · doi:10.1111/cas.16459 · Cited by 3
Self-citation
PARP Inhibitors in Genitourinary Cancer: A New Paradigm Beyond Prostate Cancer
Okuda, Y., Kato, T., Ishizuya, Y., Hayashi, T., Yamamoto, Y., Hatano, K., Kawashima, A., Murai, J., & Nonomura, N. (2025) · International Journal of Urology · doi:10.1111/iju.70100 · Cited by 4
Prostate cancer germline variants with therapeutic implications
Bitaraf, M., Castro, E., & Sharifi, N. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.07.004 · Cited by 3
Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations
Ostrowski, M., Jo, Y., Chehade, C. H., Özay, Z. İ., Gebrael, G., Sayegh, N., Lin, E., Srivastava, A., Gordhamer, A., Ji, R., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.34968 · Cited by 3
Identification of Actionable Mutations in Metastatic Castration-Resistant Prostate Cancer Through Circulating Tumor DNA: Are We There Yet?
Tao, W., Sabel, A. R., & Bonfil, R. D. (2025) · Current Oncology · doi:10.3390/curroncol32120692 · Cited by 3
PARP Inhibitor Olaparib and Its Combination Therapy in Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-analysis
Li, Y., Li, Z., Lu, H., Shi, P., Liu, Y., Liu, L., & Chen, K. (2025) · European Urology Open Science · doi:10.1016/j.euros.2025.12.014 · Cited by 3
Genomic landscape and precision therapy in prostate cancer: current status and future directions
Ligon, J. A., Anand, S., Singh, S., Siddiqui, J. A., Henegan, J. C., & Singh, A. P. (2026) · npj Precision Oncology · doi:10.1038/s41698-026-01368-3 · Cited by 3
Phase II study of olaparib and durvalumab in patients with metastatic castration-resistant prostate cancer
Li, C., Madan, R. A., Lee, M.-J., Lee, S., Sato, N., Rastogi, S., Shrestha, R. L., Aragon‐Ching, J. B., Goswami, M., Donahue, R. N., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014365 · Cited by 3
Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE)
McKay, R. R., Xie, W., Ajmera, A., Araneta, A., Jamieson, C. E., Folefac, E., Hussain, A., Kyriakopoulos, C. E., Manning, D. K., Olson, A., et al. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-02835 · Cited by 3
Testing BRCA 1-2 Mutations in Metastatic Prostate Cancer: Results of a Survey of the Italian Association of Medical Oncology
Saporita, I., Calabrese, M., Poletto, S., Turco, F., Stefano, R. F. D., Caffo, O., Russo, A. G., Giorgi, U. D., Tucci, M., Maïo, M. D., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102255 · Cited by 3
The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials
Pinterpe, G., Migliaccio, F., Ciccarese, C., Pedone, R. R., Belletto, R., Russo, P., Totaro, A., Tagliaferri, L., Sighinolfi, M. C., Formisano, L., et al. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01141-9 · Cited by 3
Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Tsung, I., Smith, D. C., Heath, E. I., Cackowski, F. C., Devitt, M. E., Braun, T., Yentz, S. E., Nguyen, C. B., Chinnaiyan, A. M., Shah, N., et al. (2025) · JCO Precision Oncology · doi:10.1200/po-25-00457 · Cited by 3
A review of treatments targeting DNA-repair gene defects in metastatic castration resistant prostate cancer
Maslov, D. V., Sember, Q., Cham, J., & Bhangoo, M. S. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1150777 · Cited by 3
A Review of the Azasteroid-type 5-alpha Reductase Inhibitors for the Management of Benign Prostatic Hyperplasia
Arya, G. C., Rathee, A., Mehla, S., Bisht, P., & Sharma, R. K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/0115701808241219230923154750 · Cited by 3
Pharmacogenomics and Precision Therapy in Prostate Cancer: Challenges and Perspectives
STEFANOVIĆ, N. Z. (2024) · Springer eBooks · doi:10.1007/978-3-031-51712-9_17 · Cited by 3
PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer
Cunningham, M. L., & Schiewer, M. J. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-3458 · Cited by 3
Homologous Recombination Repair Testing Patterns and Outcomes in mCRPC by Alteration Status and Race
Bilen, M. A., Khilfeh, I., Rossi, C., Muser, E., Morrison, L., Hilts, A., Diaz, L., Lefèbvre, P., Pilon, D., & George, D. J. (2024) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s468680 · Cited by 3
Talazoparib plus enzalutamide versus olaparib plus abiraterone acetate and niraparib plus abiraterone acetate for metastatic castration-resistant prostate cancer: a matching-adjusted indirect comparison
Castro, E., Wang, D., Walsh, S., Craigie, S., Haltner, A., Nazari, J. L., Niyazov, A., & Samjoo, I. A. (2024) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-024-00924-x · Cited by 3
Nouvelles AMM : olaparib en combinaison à l’abiratérone dans le cancer de la prostate métastatique résistant à la castration
Sabouret, A., & Beuzeboc, P. (2023) · Bulletin du Cancer · doi:10.1016/j.bulcan.2023.01.015 · Cited by 3
Acting on Actionable Mutations in Metastatic Prostate Cancer
Marshall, C. H. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00350 · Cited by 3
Rucaparib monotherapy in the heavily pre-treated metastatic castrate-resistant prostate cancer setting: practical considerations and alternate treatment approaches
Sayyid, R. K., Bernardino, R. M. M., Chavarriaga, J., Gleave, A., Kumar, R., & Fleshner, N. E. (2024) · Translational Andrology and Urology · doi:10.21037/tau-23-671 · Cited by 3
Breaking barriers: Deciphering the mechanisms of Olaparib resistance in prostate cancer
El‐Sehrawy, A. A. M. A., Mukhlif, M. Y., Khalaf, A. A., Uthirapathy, S., Ballal, S., Singh, A., Kavitha, V. S. N. P., Maharana, L., Ridha‐Salman, H., & Al-Altememe, A. R. H. (2025) · Seminars in Oncology · doi:10.1016/j.seminoncol.2025.152375 · Cited by 2
Liquid biopsy in prostate cancer: A multidisciplinary expert consensus statement
Pepe, F., Seminati, D., Baldassarre, G., Cirmena, G., de Biase, D., di Celle, P. F., Guerini‐Rocco, E., Melucci, E., Minucci, A., Moserle, L., et al. (2025) · Tumori Journal · doi:10.1177/03008916251379317 · Cited by 2
Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer
Fred Saad, C., Armstrong, A. J., Oya, M., Shore, N. D., Procopio, G., Guedes, J. D., Arslan, C., Mehra, N., Brown, E., Joung, J. Y., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.10.010 · Cited by 3
Self-citation
PARP Inhibition in Prostate Cancer: Current Status, Resistance Mechanisms, and Clinical Challenges
Matsuoka, T., Akamatsu, S., Ong, C. J., Gleave, M. E., & Wang, Y. (2026) · Cells · doi:10.3390/cells15070588 · Cited by 3
Evaluation of novel treatments for metastatic castration-resistant prostate cancer
Güner, G., & Arslan, Ç. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2652456 · Cited by 2
Evolving Systemic Therapy for Prostate Cancer: Pivotal Clinical Trials, Biomarker-Driven Combinations, and Practical Sequencing in the ARSI–PARP–Radioligand Era
Somoto, T., Utsumi, T., Ikeda, R., Sugimoto, T., Ishitsuka, N., Kadono, Y., Noro, T., Suzuki, Y., Iijima, S., Sugizaki, Y., et al. (2026) · Cancers · doi:10.3390/cancers18121966 · Cited by 2
Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer
Hooper, G., Jo, Y., Nandakumar, V., Gebrael, G., Özay, Z. İ., Ostrowski, M., Hardy, T., Lin, E., Campbell, P., Murdock, E. G., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.20750 · Cited by 2
Advances in systemic therapies for advanced prostate cancer
Childs, D. S., Hahn, A. W., Ravi, P. K., & Orme, J. J. (2026) · BMJ · doi:10.1136/bmj-2025-085211 · Cited by 2
PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers
Santos, E. S. D., Cicilini, A. L., Simões, M. F. E., Baz, M., Caputo, S. M., & Rouleau, É. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156754 · Cited by 2
Beyond androgen deprivation therapy: Next-generation hormonal therapies and emerging combination approaches in advanced prostate cancer
Paras, G., & Schweizer, M. T. (2026) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2026.07.014 · Cited by 2
PARP Inhibitors in Colorectal Malignancies: A 2023 Update
Skouteris, N., & provided, G. N. (2023) · Reviews on Recent Clinical Trials · doi:10.2174/0115748871260815231116060817 · Cited by 2
Determining magnitude of benefit from poly(ADP-ribose) polymerase inhibitors in prostate cancer
Akbıyık, İ., & Ürün, Y. (2023) · Future Oncology · doi:10.2217/fon-2023-0550 · Cited by 2
Carboplatin and Etoposide for the Treatment of Metastatic Prostate Cancer with or without Neuroendocrine Features: A French Single-Center Experience
Baude, J., Niogret, J., Jacob, P., Bardet, F., Desmoulins, I., Zanetta, S., Kaderbhaï, C., Galland, L., Mayeur, D., Delattre, B., et al. (2024) · Cancers · doi:10.3390/cancers16020280 · Cited by 2
Molekulare Testung des Prostatakarzinoms: wann, wie und mit welcher Konsequenz?
Amsberg, G. V., & Paulsen, F. (2024) · Aktuelle Urologie · doi:10.1055/a-2266-3607 · Cited by 2
Germline and somatic mutations in prostate cancer: Implications for treatment
Chalker, C., Chun, B., & Sokolova, A. O. (2024) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2024.101101 · Cited by 2
Diagnostics and treatment of BRCA-associated cancers with olaparib — expert position statement
Kowalik, A., Chudecka-Glaz, A. M., Kufel-Grabowska, J., Skoneczna, I., & Kubiatowski, T. (2024) · Oncology in Clinical Practice · doi:10.5603/ocp.99216 · Cited by 2
Prognostic value of germline mutations in metastatic hormone-sensitive prostate cancer (mHSPC)
Custodio‐Cabello, S., Pacheco-Barcía, V., Palka-Kotlowska, M., Fernández-Hernández, L., Álamo, J. F. D., Acebes, E. O., & Cabezón‐Gutiérrez, L. (2024) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2024.05.010 · Cited by 2
Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO ‐2 Japanese Subgroup Analysis
Matsubara, N., Miyake, H., Uemura, H., Mizokami, A., Kikukawa, H., Kosaka, T., Nishimura, K., Nakamura, M., Kobayashi, K., Komaru, A., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70333 · Cited by 2
The emerging regulatory interface between DNA repair and steroid hormone receptors in cancer
de Klein, B., Eickhoff, N., & Zwart, W. T. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.01.006 · Cited by 3
Toxicities of PARP inhibitors in genitourinary cancers
Szalontai, J., Szarvas, T., Miszczyk, M., Nyírády, P., Shariat, S. F., & Fazekas, T. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001297 · Cited by 2
Pulmonary Embolism Associated with Olaparib in BRCA2-Mutated Prostate Cancer: A Case Report
Ishii, S., Maekawa, S., Amano, F., Kikuchi, D., Ikarashi, D., Kato, R., Kanehira, M., Takata, R., Sugimura, J., & Obara, W. (2025) · Current Oncology · doi:10.3390/curroncol32090523 · Cited by 2
Mise au point et stratégies thérapeutiques dans le cancer de la prostate avancé et métastatique
Denis, C., & Sautois, B. R. (2023) · Médecine Nucléaire · doi:10.1016/j.mednuc.2023.09.003 · Cited by 3
Arterial hypertension associated with PARPi: A meta‐analysis of 41 placebo randomized controlled trials combined with a World Health Organization's pharmacovigilance study
Blaize, C., Surtouque, E., Font, J., Dolladille, C., Postel-Vinay, S. C., Silva, A. D., Alexandre, J., & Morice, P. (2024) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.12984 · Cited by 2
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations
Bobbili, P. J., Ivanova, J. I., Solit, D. B., Mettu, N. B., McCall, S. J., Dhawan, M., DerSarkissian, M., Arondekar, B. V., Chang, J., Niyazov, A., et al. (2024) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2024.102080 · Cited by 2
Assessment of Patient and Clinician Perspectives on Clinically Meaningful Extension of Progression-free Survival in Prostate Cancer
Oh, E. L., Huish, W., El-Gamil, S., Benson, T., & Ferguson, T. (2024) · European Urology Open Science · doi:10.1016/j.euros.2024.10.018 · Cited by 2
Genomic and transcriptomic sequencing in prostate cancer
Rifai, S., Rifai, A., Shi, X., Khan, M. A., Guang, W., Wang, L., Tallon, L. J., & Hussain, A. (2025) · Current Opinion in Oncology · doi:10.1097/cco.0000000000001136 · Cited by 2
Management of Metastatic Prostate Cancer
Amsberg, G. V., Busenbender, T., Coym, A., Kaune, M., Strewinsky, N., Ekrutt, J., Tilki, D., & Dyshlovoy, S. A. (2025) · Oncology Research and Treatment · doi:10.1159/000546930 · Cited by 3
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer
Abida, W. M., & Attard, G. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01123-6 · Cited by 2
Poly-ADP ribose polymerase inhibitor and androgen receptor signaling inhibitor for all comers for first-line treatment of metastatic castration-resistant prostate cancer: is gene sequencing out?
Higano, C. S., & Cheng, H. H. (2023) · Current Opinion in Urology · doi:10.1097/mou.0000000000001114 · Cited by 2
Individualisierte Präzisionsmedizin
Wullich, B., Taubert, H. W., Goebell, P. J., Kuwert, T., Beck, M., Schott, C., Baur, A. S., Eckstein, M., & Wach, S. (2023) · Die Urologie · doi:10.1007/s00120-023-02151-z · Cited by 2
Efficacy and safety of olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis of randomized controlled trials
Luo, Z., Zhu, B., Xu, H., Chen, L., Song, X., Wang, Y., Wang, R., Zheng, J., Qiu, Y., Yang, J., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1265276 · Cited by 2
Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial
Armstrong, A. J., Clarke, N. W., Oya, M., Procopio, G., de Menezes, J., Guedes, J. D., Ghatalia, P., Nolè, F., Din, O. S., Spiegelhalder, P., et al. (2023) · European Urology Oncology · doi:10.1016/j.euo.2023.10.004 · Cited by 2
Self-citation
Addition of Olaparib to the New Hormonal Agent Regimen for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
Warli, S. M., Velaro, A. J., Firsty, N. N., & Tala, Z. Z. (2023) · World Journal of Oncology · doi:10.14740/wjon1685 · Cited by 2
Que retenir dans la prise en charge des cancers en 2022 ?
Bay, J., Bouleuc, C., Caux, C., Delom, F., Firmin, N., Gandemer, V., L’Allemain, G., Magné, N., Orbach, D. H., Robert, J., et al. (2022) · Bulletin du Cancer · doi:10.1016/j.bulcan.2022.12.002 · Cited by 2
Self-citation
Poly (ADP-ribose) polymerase inhibitor: A new horizon in advanced prostate cancer treatment
Kang, M., & Jeon, S. S. (2023) · Korean journal of urology · doi:10.4111/icu.20230185 · Cited by 2
Novel therapies for metastatic prostate cancer
Jang, A., Lanka, S. M., Ruan, H. T., Kumar, H. L. S., Jia, A. Y., Garcia, J. A., Mian, O. Y., & Barata, P. C. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2290197 · Cited by 1
Poly-ADP Ribose Polymerase Inhibitors and Combinations in Metastatic Prostate Cancer
Ababneh, O. E., & McKay, R. R. (2025) · Advances in Oncology · doi:10.1016/j.yao.2024.12.008 · Cited by 1
Population Pharmacokinetics of Cobicistat and its Effect on the Pharmacokinetics of the Anticancer Drug Olaparib
Overbeek, J. K., van Erp, N. P., Burger, D. M., den Broeder, A. A., Koolen, S. L. W., Huitema, A. D. R., & ter Heine, R. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01480-w · Cited by 1
Genetic and Non-Genetic Risk Factors in Prostate Cancer: Towards a Precision Medicine Approach
Hloušek, S., Argalácsová, S., Soukupová, J., Záleský, M., Jurok, M., & Vočka, M. (2025) · Folia Biologica · doi:10.14712/fb2025071030095 · Cited by 1
Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study
Armstrong, A. J., Fred Saad, C., Oya, M., Vianna, K., Özgüroğlu, M., Gedye, C. A., Buchschacher, G. L., Lee, J. Y., Emmenegger, U., Navrátil, J., et al. (2025) · European Urology Oncology · doi:10.1016/j.euo.2025.09.010 · Cited by 2
Self-citation
Twelve mutations, three trials, and five different labels: PARP inhibitors regulatory inconsistencies in prostate cancers
van Doorn-Khosrovani, S. B. V. W., Westgeest, H. M., & Olivier, T. (2025) · EClinicalMedicine · doi:10.1016/j.eclinm.2025.103725 · Cited by 1
Carboplatin, Cabazitaxel, and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase II Study
Antonarakis, E. S., Cao, Q., Catharine, V., Carneiro, B. A., Souza, A., VanderWeele, D. J., Singh, P., Bryce, A. H., Kelly, W. K., Jha, G. G., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-4823 · Cited by 1
Systemic Treatments of Castration-Resistant Prostate Cancer
Desai, A. N., Fleyshman, M., Lall, N., & Saraiya, B. (2026) · Urologic Clinics of North America · doi:10.1016/j.ucl.2026.02.013 · Cited by 1
Characterizing Response to PARP Inhibitor Treatment Combinations in Advanced Prostate Cancer
Gonzalez, B. C., Karthikeyan, A., Moore, L. A., Bhaumik, A., Sandoval, E., Hardy, M., McPherson, J. D., Li, H., Parikh, M., Dall’Era, M., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14050949 · Cited by 1
Precision Medicine in Prostate Cancer
Dimitrov, G., & Popov, E. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_4 · Cited by 1
PARP Inhibitor Plus Androgen-receptor Signaling Inhibitor Versus the Same Inhibitor Alone in Homologous-Recombination-Repair-Altered Metastatic Prostate Cancer Across the Hormone-Sensitive and Castration-Resistant Continuum: A Systematic Review and Meta-Analysis
Su, Y., Wu, R., Pan, H., & Yuan, H. (2026) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2026.102629 · Cited by 1
Exploratory Time‐Dependent Patterns in Estimated Treatment Effect of Talazoparib Plus Enzalutamide in HRR Non‐Deficient or Unknown Metastatic Castration‐Resistant Prostate Cancer: A Post Hoc Analysis of the TALAPRO ‐2 Trial
Yajima, S., Yoshida, S., Chen, W., Fukushima, H., Tanaka, H., Sato, H., Hirakawa, A., Masuda, H., & Fujii, Y. (2026) · International Journal of Urology · doi:10.1111/iju.70582 · Cited by 1
Bridging the gap: integrating hereditary cancer into precision oncology
Aron, M. A. R., Cruellas, M., & Balmañà, J. (2026) · European Journal of Human Genetics · doi:10.1038/s41431-026-02196-6 · Cited by 1
Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel
Shore, N. D., Clarke, N. W., Armstrong, A. J., Oya, M., Procopio, G., Guedes, J. D., Arslan, Ç., Mehra, N., Brown, E., Joung, J. Y., et al. (2026) · European Urology Oncology · doi:10.1016/j.euo.2026.07.014 · Cited by 1
Self-citation
Management of de Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) and the Role of Radiation Therapy: A Consensus by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)
Lancia, A., Alitto, A. R., Pappagallo, G. L., Ciurlia, E., Francolini, G., D’Angelillo, R. M., Fersino, S., Giaj‐Levra, N., Jereczek-Fossa, B. A., Magli, A., et al. (2024) · Practical Radiation Oncology · doi:10.1016/j.prro.2024.10.007 · Cited by 1

Authors: Clarke, N. W., Armstrong, A. J., Thiery-Vuillemin, A., Oya, M., Shore, N., Loredo, E., Procopio, G., de Menezes, J., Girotto, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Schlürmann, F., Joung, J. Y., Sugimoto, M., Virizuela, J. A., Emmenegger, U., Navratil, J., Buchschacher, G. L., Poehlein, C., Harrington, E. A., Desai, C., Kang, J., & Saad, F.
Affiliations: University of Manchester (GB)
Duke University (US)
Centre Hospitalier Universitaire de Besançon (FR)
Keio University (JP)
Carolina Urologic Research Center (US)
Centro de Investigaciones Clinicas Viña del Mar, Valparaíso, Chile
Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Hospital Nossa Senhora da Conceição (BR)
Hospital de Base (BR)
Izmir Economy University Medical Park Hospital, Karsiyaka, Turkey
Radboud University Medical Center (NL)
Ashford Cancer Centre Research, Adelaide, South Australia
University Hospital Southampton NHS Foundation Trust (GB)
Centre Hospitalier de Cornouaille (FR)
National Cancer Center (KR)
Kagawa University Hospital (JP)
Hospital Universitario Virgen Macarena (ES)
Sunnybrook Research Institute (CA)
Masaryk Memorial Cancer Institute, Brno, Czech Republic
Kaiser Permanente (US)
Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
AstraZeneca (United Kingdom) (GB)
AstraZeneca (United States) (US)
Centre Hospitalier de l’Universite de Montreal, Montreal
ORCID: Clarke, Noel W.
Armstrong, Andrew J.
Thiery-Vuillemin, Antoine
Oya, Mototsugu
Shore, Neal
Procopio, Giuseppe
Girotto, Gustavo
Mehra, Niven
Joung, Jae Y.
Sugimoto, Mikio
Virizuela, Juan A.
Emmenegger, Urban
Buchschacher, Gary L.
Poehlein, Christian
Harrington, Elizabeth A.
Kang, Jinyu
Venue: NEJM Evidence
Publisher: Massachusetts Medical Society
Published: 2022-08-23
Volume: 1
Issue: 9
Pages: EVIDoa2200043-EVIDoa2200043
ISSN: 2766-5526 (ISSN-L)
DOI: 10.1056/evidoa2200043
OpenAlex: W4281770555
Cited by: 426
References: 27
Citations by year: 2026: 77 · 2025: 108 · 2024: 111 · 2023: 110 · 2022: 20
FWCI: 56.30
Type: journal article
Language: en
Open access: closed
Locations: NEJM Evidence (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: abiraterone, olaparib, metastatic castration-resistant prostate cancer, PARP inhibitors, first-line therapy, homologous recombination deficiency, progression-free survival, overall survival, combination therapy, PARP inhibitor resistance, circulating tumor DNA, anemia, fatigue, nausea, hormone therapy
MeSH terms: Androstenes, Antineoplastic Combined Chemotherapy Protocols, Humans, Male, Phthalazines, Piperazines, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks